Lorine Arias Bonifácio Teixeira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lorine Arias Bonifácio Teixeira has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Ademar Lucas Júnior1 shared publication
- Bruna Salani Mota
Instituto do Câncer do Estado de São Paulo, Sao Paulo, SP, Brazil
1 shared publication - Bruno Salvador Sobreira Lima
Department of Mastology, Division of Gynecology and Obstetrics, Faculty of Medicine of University of São Paulo, University of São Paulo, Sao Paulo, Brazil
1 shared publication - Diego Wallace Nascimento
Department of Mastology, Division of Gynecology and Obstetrics, Faculty of Medicine of University of São Paulo, University of São Paulo, Sao Paulo, Brazil
1 shared publication - Edmund Chada Baracat
Laboratório de Ginecologia Estrutural e Molecular (LIM 58), Disciplina de Ginecologia, Departamento de Obstetrícia e Ginecologia, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, SP, Brazil
1 shared publication - Gabriela Boufelli de Freitas
Department of Mastology, Division of Gynecology and Obstetrics, Faculty of Medicine of University of São Paulo, University of São Paulo, Sao Paulo, Brazil
1 shared publication
Latest Publications
- Open Access
- 16 April 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Impact of COVID-19 on breast cancer care - a retrospective cohort study in Brazil
Background: The COVID-19 pandemic disrupted healthcare systems worldwide and substantially affected breast cancer care. International reports have described delays in diagnosis, stage, and modifications in treatment strategies, however, little is known about how the pandemic has affected the entire sequence of steps from diagnosis to treatment initiation and completion within the Brazilian public healthcare system. Methods: This retrospective cohort study followed the STROBE guidelines and was conducted at a high-volume public cancer center in São Paulo, Brazil. A total of 1,306 women diagnosed with invasive or in situ breast cancer were included: 755 patients in the prepandemic period (March 2018–February 2019) and 551 patients in the pandemic period (March 2020–February 2021). Clinical, pathological, treatment, and time-related variables along the care pathway were extracted from electronic medical records and compared using appropriate statistical tests, with significance set at p < 0.05. Results: A 32% reduction in the number of treated patients occurred during the pandemic (551 vs. 755). Patients who were diagnosed during the pandemic were younger (48.3 vs. 53.6 years; p < 0.001) and presented with more advanced clinical stages, including higher rates of cT3–T4 tumors and nodal involvement ( p < 0.001). The use of neoadjuvant therapy increased from 36.8% to 49%, particularly among early-stage and luminal B tumors. Key intervals across the care pathway were significantly prolonged, including time to initial treatment and completion of adjuvant therapy. Radiotherapy practices have shifted toward hypofractionated protocols. Conclusion: The first year of the COVID-19 pandemic was associated with fewer treated patients, stage migration toward more advanced disease, greater reliance on neoadjuvant therapy, and prolonged time intervals along the care pathway from diagnosis to treatment initiation and completion. These findings highlight the need for resilient oncology systems, protected treatment pathways, and strengthened care coordination to mitigate the impact of future healthcare crises.
- 16 April 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessImpact of COVID-19 on breast cancer care - a retrospective cohort study in Brazil
Background: The COVID-19 pandemic disrupted healthcare systems worldwide and substantially affected breast cancer care. International reports have described delays in diagnosis, stage, and modifications in treatment strategies, however, little is known about how the pandemic has affected the entire sequence of steps from diagnosis to treatment initiation and completion within the Brazilian public healthcare system. Methods: This retrospective cohort study followed the STROBE guidelines and was conducted at a high-volume public cancer center in São Paulo, Brazil. A total of 1,306 women diagnosed with invasive or in situ breast cancer were included: 755 patients in the prepandemic period (March 2018–February 2019) and 551 patients in the pandemic period (March 2020–February 2021). Clinical, pathological, treatment, and time-related variables along the care pathway were extracted from electronic medical records and compared using appropriate statistical tests, with significance set at p < 0.05. Results: A 32% reduction in the number of treated patients occurred during the pandemic (551 vs. 755). Patients who were diagnosed during the pandemic were younger (48.3 vs. 53.6 years; p < 0.001) and presented with more advanced clinical stages, including higher rates of cT3–T4 tumors and nodal involvement ( p < 0.001). The use of neoadjuvant therapy increased from 36.8% to 49%, particularly among early-stage and luminal B tumors. Key intervals across the care pathway were significantly prolonged, including time to initial treatment and completion of adjuvant therapy. Radiotherapy practices have shifted toward hypofractionated protocols. Conclusion: The first year of the COVID-19 pandemic was associated with fewer treated patients, stage migration toward more advanced disease, greater reliance on neoadjuvant therapy, and prolonged time intervals along the care pathway from diagnosis to treatment initiation and completion. These findings highlight the need for resilient oncology systems, protected treatment pathways, and strengthened care coordination to mitigate the impact of future healthcare crises.
- 1 May 2022
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 42 (3) , 806-821
Adverse Radiation Therapy Effects in the Treatment of Head and Neck Tumors
Radiation therapy has an essential role in the treatment of head and neck malignancies, but radiation-induced adverse effects remain a clinical issue and are recognizable at CT and MRI. Whether used as a single modality or as part of a combined approach, radiation therapy (RT) plays an essential role in the treatment of several head and neck malignancies. Despite the improvement i...
- 1 May 2022
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 42 (3) , 806-821
Adverse Radiation Therapy Effects in the Treatment of Head and Neck Tumors
Radiation therapy has an essential role in the treatment of head and neck malignancies, but radiation-induced adverse effects remain a clinical issue and are recognizable at CT and MRI. Whether used as a single modality or as part of a combined approach, radiation therapy (RT) plays an essential role in the treatment of several head and neck malignancies. Despite the improvement i...